Moderna is trading 4.16% lower at $194.20 after investors reportedly treated positive Phase 3 melanoma vaccine results as a sell-the-news event. - On Oct. 22, shares fell 17.57% to $202.63. - Phase 3 results with Merck showed the personalized melanoma vaccine combination cut recurrence-or-death risk by 42%; data appeared online before its scheduled presentation. - Broader risk-off sentiment was also noted, but the vaccine reaction was the clearest catalyst. No new Oct. 23 Moderna announcement appeared in available search results.